How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries-Reference-Cited by-同舟云学术

How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries

Published:2015-11-30 Issue:10 Volume:75 Page:1789-1796
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Askling Johan,Berglind Niklas,Franzen Stefan,Frisell Thomas^ORCID,Garwood Christopher,Greenberg Jeffrey D,Ho Meilien,Holmqvist Marie,Horne Laura,Inoue Eisuke,Michaud Kaleb^ORCID,Nyberg Fredrik^ORCID,Pappas Dimitrios A,Reed George,Tanaka Eiichi,Tran Trung N,Verstappen Suzanne M M,Yamanaka Hisashi,Wesby-van Swaay Eveline,Symmons Deborah^ORCID

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference21 articles.

1. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis;Smitten;Arthritis Res Ther,2008

2. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data;Askling;Pharmacoepidemiol Drug Saf,2011

3. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy;Taylor;Ann Rheum Dis,2015

4. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study;Weinblatt;Arthritis Rheumatol,2014

5. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach;Nyberg;Pharmacoepidemiol Drug Saf,2015

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial;Arthritis Research & Therapy;2024-07-29

2. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study;RMD Open;2024-07

3. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study;RMD Open;2024-05

4. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook;Expert Review of Clinical Immunology;2023-08-14

5. CD73/NT5E is a Potential Biomarker for Cancer Prognosis and Immunotherapy for Multiple Types of Cancers;Advanced Biology;2022-12-08